Cargando…
Dependence On Glycolysis Sensitizes BRAF-mutated Melanomas For Increased Response To Targeted BRAF Inhibition
Dysregulated metabolism can broadly affect therapy resistance by influencing compensatory signaling and expanding proliferation. Given many BRAF-mutated melanoma patients experience disease progression with targeted BRAF inhibitors, we hypothesized therapeutic response is related to tumor metabolic...
Autores principales: | Hardeman, Keisha N., Peng, Chengwei, Paudel, Bishal B., Meyer, Christian T., Luong, Thong, Tyson, Darren R., Young, Jamey D., Quaranta, Vito, Fessel, Joshua P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5311997/ https://www.ncbi.nlm.nih.gov/pubmed/28205616 http://dx.doi.org/10.1038/srep42604 |
Ejemplares similares
-
Purinergic calcium signaling drives drug tolerance through ERK reactivation in BRAF-mutant melanoma
por: Stauffer, Philip E., et al.
Publicado: (2023) -
Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma
por: Spagnolo, Francesco, et al.
Publicado: (2014) -
BRAF activation by metabolic stress promotes glycolysis sensitizing NRAS(Q61)-mutated melanomas to targeted therapy
por: McGrail, Kimberley, et al.
Publicado: (2022) -
Drug-Tolerant Idling Melanoma Cells Exhibit Theory-Predicted Metabolic Low-Low Phenotype
por: Jia, Dongya, et al.
Publicado: (2020) -
Imaging markers of response to combined BRAF and MEK inhibition in BRAF mutated vemurafenib-sensitive and resistant melanomas
por: Acciardo, Stefania, et al.
Publicado: (2018)